Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Assessing meaningful change in quality of life over time: a users' guide for clinicians.

Sprangers MA, Moinpour CM, Moynihan TJ, Patrick DL, Revicki DA; Clinical Significance Consensus Meeting Group.

Mayo Clin Proc. 2002 Jun;77(6):561-71. Review.

PMID:
12059127
2.

The clinical significance of quality-of-life results: practical considerations for specific audiences.

Symonds T, Berzon R, Marquis P, Rummans TA; Clinical Significance Consensus Meeting Group.

Mayo Clin Proc. 2002 Jun;77(6):572-83. Review.

PMID:
12059128
3.

Assessment of quality of life during chemotherapy.

Gunnars B, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):175-84. Review.

PMID:
11441930
4.

First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.

[No authors listed]

Prescrire Int. 2013 Feb;22(135):48-51. Review.

PMID:
23444510
5.

Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma.

Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, Wilt TJ, Aronson N.

Cancer. 2002 Jul 15;95(2):361-76. Review.

6.

Quality of life in oncology trials: a clinical guide.

Movsas B.

Semin Radiat Oncol. 2003 Jul;13(3):235-47. Review.

PMID:
12903013
7.

Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.

McNaughton-Collins M, Walker-Corkery E, Barry MJ.

J Natl Cancer Inst Monogr. 2004;(33):78-101. Review.

PMID:
15504921
8.
9.
10.

Quality of life research in head and neck cancer: a review of the current state of the science.

Murphy BA, Ridner S, Wells N, Dietrich M.

Crit Rev Oncol Hematol. 2007 Jun;62(3):251-67. Epub 2007 Apr 3. Review.

PMID:
17408963
11.

[First line therapy in the treatment of metastatic prostate cancer].

Sakai H, Kanetake H.

Gan To Kagaku Ryoho. 2003 Jan;30(1):43-9. Review. Japanese.

PMID:
12557704
12.

Quality of life in patients with traumatic brain injury-basic issues, assessment and recommendations.

Bullinger M, Azouvi P, Brooks N, Basso A, Christensen AL, Gobiet W, Greenwood R, Hütter B, Jennett B, Maas A, Truelle JL, von Wild KR; TBI Consensus Group.

Restor Neurol Neurosci. 2002;20(3-4):111-24. Review.

PMID:
12454360
13.

[Treatment of advanced prostatic cancer].

Hedlund PO.

Lakartidningen. 2000 Aug 9;97(32-33):3466-9. Review. Swedish.

PMID:
11037588
14.

Locally advanced prostate cancer: effective treatments, but many adverse effects.

[No authors listed]

Prescrire Int. 2013 Jan;22(134):18-20, 22-3. Review.

PMID:
23367679
15.

Quality of life in randomized trials of cytotoxic or hormonal treatment of advanced breast cancer. Is there added value?

Fossati R, Confalonieri C, Mosconi P, Pistotti V, Apolone G.

Breast Cancer Res Treat. 2004 Oct;87(3):233-43. Review.

PMID:
15528966
16.
17.

Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer.

Kolvenbag GJ, Iversen P, Newling DW.

Urology. 2001 Aug;58(2 Suppl 1):16-23. Review.

PMID:
11502439
18.

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Nair B, Wilt T, MacDonald R, Rutks I.

Cochrane Database Syst Rev. 2002;(1):CD003506. Review.

PMID:
11869665
19.

Quality of life measurements: a soft outcome--or is it?

Frost MH, Sloan JA.

Am J Manag Care. 2002 Dec;8(18 Suppl):S574-9. Review.

20.

Life after failure of traditional androgen deprivation therapy.

Schellhammer P.

Urol Oncol. 2012 Jul-Aug;30(4 Suppl):S10-4. doi: 10.1016/j.urolonc.2012.01.009. Review.

PMID:
22795075

Supplemental Content

Support Center